Drug intelligence / Profile preview

HRF-2105

Development stage: Phase 2
Lead developer: Hengrui Pharmaceutical
Modality: Small Molecules
Administration: Transdermal

Overview

HRF-2105 is an investigational drug developed by Jiangsu Hengrui Pharmaceuticals. It is being studied primarily for the treatment of pain associated with osteoarthritis and other nervous system-related conditions. The drug is administered via a transdermal patch. As of the latest available information, its mechanism of action remains unknown, and it has not received any FDA designation or approval. Clinical development has reached Phase 2 trials for osteoarthritis pain relief[1][2][3][4].

Beyond the preview

Go deeper on HRF-2105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRF-2105.

Explore the full profile